September 2026—Pillar Biosciences, LC-SCRUM-Asia, and LSI Medience Corp. are collaborating to support the genomic screening of blood-based samples from patients with lung cancer as part of the LC-SCRUM-Asia project in Japan. The participating organizations plan to begin testing following approval of a revision to the LC-SCRUM-Asia project protocol.
“Rapid and reliable genomic testing is essential for identifying patients who may benefit from biomarker-driven clinical studies and emerging precision therapies,” Dr. Koichi Goto of LC-SCRUM-Asia, said in a joint press release. “The use of OncoReveal Essential+ through LSI Medience will provide the LC-SCRUM-Asia network with a highly accurate and accessible liquid biopsy solution for analyzing cfDNA and cfRNA from patients with non-small cell lung cancer, while supporting the rapid turnaround needed for clinical research.”
Pillar’s OncoReveal Essential+ assay has been validated at LSI Medience for use as a screening test for circulating cfDNA and cfRNA samples collected from patients with lung cancer participating in the LC-SCRUM-Asia project. Testing will be performed by LSI Medience to support identification of genomic alterations relevant to the project’s research objectives. The project is expected to include about 2,000 patients over a two-year period.
Pillar Biosciences, 800-514-9307